Herpes Simplex Virus (HSV)

Aug 14, 2026

Summary On August 6, 2026, the FDA granted accelerated approval to Replimune’s TUDRIQEV (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with Bristol Myers Squibb’s OPDIVO (nivolumab). The therapy is indicated for adults with unresectable, advanced cutaneous melanoma whose disease has ...

Dec 23, 2014

Gene Therapy to “block” Infectious disorders! Until recently, the idea of genetically modifying a person’s immune system to make it resistant to infectious disorders like HIV was considered so impractical that it belonged in the realm of science fiction. However over the past year or so, an accumulation of new dat...